Xperi (NASDAQ:XPER) reported quarterly sales of $234.00 million which beat the analyst consensus estimate of $223.76 million by 4.58 percent. This is a 5.28 percent increase over sales of $222.27 million the same period last year.
SCYNEXIS Shares Climb As FDA Accepts Filing For Vaginal Yeast Infection Candidate Under Priority Review
SCYNEXIS (NASDAQ: SCYX) announced that the U.S. Food and Drug Administration (FDA) has accepted its submission of a supplemental New Drug Application (sNDA) to expand the label of BREXAFEMME (ibrexafungerp tablets) to include the prevention of recurrent vulvovaginal candidiasis (RVVC).
